<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611154</url>
  </required_header>
  <id_info>
    <org_study_id>84225</org_study_id>
    <nct_id>NCT02611154</nct_id>
  </id_info>
  <brief_title>Intranasal Delivery of Testosterone and Its Effect on Doping Markers</brief_title>
  <acronym>Intranasal</acronym>
  <official_title>Intranasal Delivery of Testosterone and Its Effect on Doping Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sports Medicine Research and Testing Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Partnership for Clean Competition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic
      profile during anti-doping testing, which is different than the profile seen when
      testosterone is administered into muscle, on skin or under the tongue.

      Objective: The investigators aim to characterize the unique steroid doping profile following
      administration of intranasal testosterone to healthy, active volunteer subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testosterone is a substance commonly abused in the sporting world despite being banned by all
      American sports leagues, international federations, and the World Anti-Doping Agency. Current
      methods employed to detect exogenously administered testosterone include direct detection
      using isotope ratio mass spectrometry (IRMS) and indirect detection using the athlete
      biological passport (ABP). However, different formulations of testosterone (oral,
      transdermal, sublingual, etc) are expected to result in characteristic IRMS profiles, affect
      the ABP readings in unique ways, and differ in their windows of detection. In 2014, a new
      formulation of testosterone, Natesto, which is administered intranasally, was FDA approved.
      Though only approved for medical use, it is expected athletes may use this product, and its
      effect on steroid doping markers has yet to be determined. Characterization of this detection
      profile is necessary for confirmation of the exact product being administered in an
      anti-doping setting. In this study, the investigators aim to understand the effects on the
      steroid doping profile following a single administration of Natesto to healthy, active
      volunteers. Windows of detection will be determined for the standard dosing of Natesto, and
      the effects on ABP markers and IRMS profiles will also be established.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Actual">January 19, 2016</completion_date>
  <primary_completion_date type="Actual">January 19, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steroid Levels in Urine Steroid Profile</measure>
    <time_frame>4 weeks of dosing for each participant</time_frame>
    <description>Participants were instructed to follow this dosing pattern:
Begin taking Intranasal Testosterone at Day 1 for 5 consecutive days (Days 1-5), then to take 2 days off (Day 6 and 7) Urine sample at Day 6 Begin taking Intranasal Testosterone at Day 8 for 5 consecutive days (Days 8-12), then to take 3 days off (Day 13, Day 14, Day 15) Urine sample at Day 13 Begin taking Intranasal Testosterone at Day 16 for 5 consecutive days (Days 16-20), then to take 2 days off (Day 21 and 22) Urine sample at Day 21 Begin taking Intranasal Testosterone at Day 23 for 5 consecutive days (Days 23-27 ), then to take 2 days off (Day 28 and 29) Urine sample at Day 28
The first day of the dosing pattern is considered Day 1 and the last day of the pattern is considered Day 29.
Samples 4-8 were analyzed between 0 and 24hours post-dose Sample 9 was analyzed 48 hours post-dose Sample 10 was analyzed 72 hours post-dose Sample 11 was analyzed one week post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suspicious Steroid Profile in Urine Samples at Baseline</measure>
    <time_frame>Day 1, Day 3, Day 5</time_frame>
    <description>Participants were asked to provide 3 urine samples at Day 1, Day 3, Day 5 to measure their baseline urinary steroid marker levels. To accommodate participant schedules, all baseline samples were collected within a two week timeframe. This outcome is measuring if any participants baseline urine samples resulted in a suspicious steroid profile. For this study, &quot;suspicious&quot; is defined as any urine sample resulting in testosterone steroid detection above 200ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Level in Blood as Measured for Safety</measure>
    <time_frame>Day 0 and Day 19</time_frame>
    <description>Testosterone level in blood to ensure safety levels of testosterone prior to (Day 0) and after the first two weeks of drug administration (Day 19). Steroid levels below the normal range were considered safe to continue study participation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Abuse of Anabolic Steroids</condition>
  <arm_group>
    <arm_group_label>Intranasal Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be receiving intranasal testosterone and will follow the same study procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.</description>
    <arm_group_label>Intranasal Testosterone</arm_group_label>
    <other_name>Natesto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Males between the ages of 18 and 35 years-old who participate in regular, moderate to
        high intensity physical activity will be recruited for the study.

        Exclusion Criteria:

          1. Individuals below the age of 18 or greater than the age of 35 on the day of enrollment

          2. Individuals who are in a Registered Testing Pool for anti-doping purposes, or
             individuals who for any reason could be subject to doping control testing.

          3. Unwilling to provide blood or urine samples

          4. Not actively exercising

          5. Individuals with any history of cancer, cardiovascular disease, endocrine
             abnormalities, renal disease, hepatic disease, neurologic disease or any psychiatric
             history

          6. Individuals with a history of nasal disorders, nasal surgeries, sinus surgeries, or
             sinus disease

          7. Individuals that have a baseline hematocrit value above the normal range

          8. Individuals that are diabetic or are currently taking a diabetic medication

          9. Individuals that are currently using any WADA prohibited substances

         10. Individuals that have recently used or currently using anabolic androgenic steroids
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Willick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saudan C, Baume N, Robinson N, Avois L, Mangin P, Saugy M. Testosterone and doping control. Br J Sports Med. 2006 Jul;40 Suppl 1:i21-4. Review.</citation>
    <PMID>16799097</PMID>
  </reference>
  <reference>
    <citation>Geyer H, Sch√§nzer W, Thevis M. Anabolic agents: recent strategies for their detection and protection from inadvertent doping. Br J Sports Med. 2014 May;48(10):820-6. doi: 10.1136/bjsports-2014-093526. Epub 2014 Mar 14. Review.</citation>
    <PMID>24632537</PMID>
  </reference>
  <reference>
    <citation>Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am. 2010 Mar;39(1):59-73, viii-ix. doi: 10.1016/j.ecl.2009.11.003.</citation>
    <PMID>20122450</PMID>
  </reference>
  <reference>
    <citation>Vernec AR. The Athlete Biological Passport: an integral element of innovative strategies in antidoping. Br J Sports Med. 2014 May;48(10):817-9. doi: 10.1136/bjsports-2014-093560. Epub 2014 Mar 21.</citation>
    <PMID>24659508</PMID>
  </reference>
  <reference>
    <citation>Jia H, Sullivan CT, McCoy SC, Yarrow JF, Morrow M, Borst SE. Review of health risks of low testosterone and testosterone administration. World J Clin Cases. 2015 Apr 16;3(4):338-44. doi: 10.12998/wjcc.v3.i4.338. Review.</citation>
    <PMID>25879005</PMID>
  </reference>
  <reference>
    <citation>Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009 Jun;5(3):427-48. Epub 2009 Jun 22.</citation>
    <PMID>19707253</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>March 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Stuart Willick</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Sports Medicine</keyword>
  <keyword>Men's Health</keyword>
  <keyword>Athletes</keyword>
  <keyword>Anti-Doping</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be published in the scientific literature.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this study began in November 2015 and ended December 2015. The final participant was enrolled on 03DEC2015 and completed the study on 19JAN2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Testosterone</title>
          <description>All participants will be receiving intranasal testosterone and will follow the same study procedures.
Testosterone: Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Testosterone</title>
          <description>All participants will be receiving intranasal testosterone and will follow the same study procedures.
Testosterone: Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Salt Lake City, Utah, USA</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steroid Levels in Urine Steroid Profile</title>
        <description>Participants were instructed to follow this dosing pattern:
Begin taking Intranasal Testosterone at Day 1 for 5 consecutive days (Days 1-5), then to take 2 days off (Day 6 and 7) Urine sample at Day 6 Begin taking Intranasal Testosterone at Day 8 for 5 consecutive days (Days 8-12), then to take 3 days off (Day 13, Day 14, Day 15) Urine sample at Day 13 Begin taking Intranasal Testosterone at Day 16 for 5 consecutive days (Days 16-20), then to take 2 days off (Day 21 and 22) Urine sample at Day 21 Begin taking Intranasal Testosterone at Day 23 for 5 consecutive days (Days 23-27 ), then to take 2 days off (Day 28 and 29) Urine sample at Day 28
The first day of the dosing pattern is considered Day 1 and the last day of the pattern is considered Day 29.
Samples 4-8 were analyzed between 0 and 24hours post-dose Sample 9 was analyzed 48 hours post-dose Sample 10 was analyzed 72 hours post-dose Sample 11 was analyzed one week post-dose</description>
        <time_frame>4 weeks of dosing for each participant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Urine Steroid Profile - Day 6</title>
            <description>Day 6 steroid level in urine. Urine sample analyzed within 24 hours of dosing.</description>
          </group>
          <group group_id="O2">
            <title>Urine Steroid Profile - Day 13</title>
            <description>Day 13 steroid level in urine. Urine sample analyzed within 24 hours of dosing.</description>
          </group>
          <group group_id="O3">
            <title>Urine Steroid Profile - Day 21</title>
            <description>Day 21 steroid level in urine. Urine sample analyzed within 24 hours of dosing.</description>
          </group>
          <group group_id="O4">
            <title>Urine Steroid Profile - Day 28</title>
            <description>Day 28 steroid level in urine. Urine sample analyzed within 24 hours of dosing.</description>
          </group>
          <group group_id="O5">
            <title>Urine Steroid Profile - Day 29</title>
            <description>Day 29 steroid level in urine. Urine sample analyzed within the 24-48 hour window post-administration.</description>
          </group>
          <group group_id="O6">
            <title>Urine Steroid Profile - Day 30</title>
            <description>Day 30 steroid level in urine. Urine sample analyzed within the 48-72 hour window post-administration.</description>
          </group>
          <group group_id="O7">
            <title>Urine Steroid Profile - Day 35</title>
            <description>Urine was collected at Day 35 to identify any suppression of endogenous testosterone production following administration.</description>
          </group>
          <group group_id="O8">
            <title>Urine Steroid Profile - Day 42</title>
            <description>Urine was collected at Day 42 to identify any suppression of endogenous testosterone production following administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Levels in Urine Steroid Profile</title>
          <description>Participants were instructed to follow this dosing pattern:
Begin taking Intranasal Testosterone at Day 1 for 5 consecutive days (Days 1-5), then to take 2 days off (Day 6 and 7) Urine sample at Day 6 Begin taking Intranasal Testosterone at Day 8 for 5 consecutive days (Days 8-12), then to take 3 days off (Day 13, Day 14, Day 15) Urine sample at Day 13 Begin taking Intranasal Testosterone at Day 16 for 5 consecutive days (Days 16-20), then to take 2 days off (Day 21 and 22) Urine sample at Day 21 Begin taking Intranasal Testosterone at Day 23 for 5 consecutive days (Days 23-27 ), then to take 2 days off (Day 28 and 29) Urine sample at Day 28
The first day of the dosing pattern is considered Day 1 and the last day of the pattern is considered Day 29.
Samples 4-8 were analyzed between 0 and 24hours post-dose Sample 9 was analyzed 48 hours post-dose Sample 10 was analyzed 72 hours post-dose Sample 11 was analyzed one week post-dose</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5773456" spread="35.54601116"/>
                    <measurement group_id="O2" value="138.0291641" spread="141.9066157"/>
                    <measurement group_id="O3" value="163.117081" spread="109.276721"/>
                    <measurement group_id="O4" value="107.7160658" spread="113.703136"/>
                    <measurement group_id="O5" value="14.15587072" spread="4.228012086"/>
                    <measurement group_id="O6" value="21.42280994" spread="14.29364856"/>
                    <measurement group_id="O7" value="32.9077285" spread="13.76180063"/>
                    <measurement group_id="O8" value="28.14492389" spread="6.661553442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epitestosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.54132527" spread="7.954646945"/>
                    <measurement group_id="O2" value="16.23444899" spread="11.98868156"/>
                    <measurement group_id="O3" value="10.08654906" spread="4.588211806"/>
                    <measurement group_id="O4" value="9.736167767" spread="4.015340993"/>
                    <measurement group_id="O5" value="12.22899541" spread="4.434891082"/>
                    <measurement group_id="O6" value="16.38534782" spread="4.918171284"/>
                    <measurement group_id="O7" value="27.76476978" spread="16.66310752"/>
                    <measurement group_id="O8" value="32.56796986" spread="10.94213563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androsterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2780.422993" spread="1545.144279"/>
                    <measurement group_id="O2" value="3147.357191" spread="2520.278196"/>
                    <measurement group_id="O3" value="3377.718911" spread="1511.306185"/>
                    <measurement group_id="O4" value="4014.439418" spread="4846.667258"/>
                    <measurement group_id="O5" value="1098.544542" spread="430.6835869"/>
                    <measurement group_id="O6" value="1689.228939" spread="968.2213645"/>
                    <measurement group_id="O7" value="2292.971167" spread="853.7596469"/>
                    <measurement group_id="O8" value="1561.824479" spread="663.1827091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etiocholanolone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3420.811467" spread="2957.358109"/>
                    <measurement group_id="O2" value="2984.088377" spread="2078.022714"/>
                    <measurement group_id="O3" value="3168.249168" spread="1630.873996"/>
                    <measurement group_id="O4" value="4614.568182" spread="7192.193898"/>
                    <measurement group_id="O5" value="1154.779419" spread="460.2075499"/>
                    <measurement group_id="O6" value="1810.282342" spread="1552.137347"/>
                    <measurement group_id="O7" value="2612.685992" spread="2105.416619"/>
                    <measurement group_id="O8" value="1281.752255" spread="372.3518874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5Œ±Adiol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.50246345" spread="28.87216828"/>
                    <measurement group_id="O2" value="70.09892435" spread="31.91867777"/>
                    <measurement group_id="O3" value="79.92660959" spread="19.82671546"/>
                    <measurement group_id="O4" value="83.39693284" spread="59.00306611"/>
                    <measurement group_id="O5" value="37.53345262" spread="7.673138406"/>
                    <measurement group_id="O6" value="51.7003489" spread="22.77519196"/>
                    <measurement group_id="O7" value="60.19484767" spread="21.91151504"/>
                    <measurement group_id="O8" value="56.94343765" spread="30.25653073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5Œ≤Adiol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.5235566" spread="95.27658018"/>
                    <measurement group_id="O2" value="370.2752839" spread="244.8399242"/>
                    <measurement group_id="O3" value="386.6496467" spread="178.3061711"/>
                    <measurement group_id="O4" value="369.209311" spread="243.4060107"/>
                    <measurement group_id="O5" value="145.5896139" spread="54.18663296"/>
                    <measurement group_id="O6" value="158.5303528" spread="90.57253904"/>
                    <measurement group_id="O7" value="166.0185686" spread="97.42880397"/>
                    <measurement group_id="O8" value="85.54384971" spread="17.46215146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suspicious Steroid Profile in Urine Samples at Baseline</title>
        <description>Participants were asked to provide 3 urine samples at Day 1, Day 3, Day 5 to measure their baseline urinary steroid marker levels. To accommodate participant schedules, all baseline samples were collected within a two week timeframe. This outcome is measuring if any participants baseline urine samples resulted in a suspicious steroid profile. For this study, &quot;suspicious&quot; is defined as any urine sample resulting in testosterone steroid detection above 200ng/mL.</description>
        <time_frame>Day 1, Day 3, Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone</title>
            <description>Testosterone level will be measured in the urine sample.</description>
          </group>
          <group group_id="O2">
            <title>Epitestosterone</title>
            <description>Epitestosterone level will be measured in the urine sample.</description>
          </group>
          <group group_id="O3">
            <title>Androsterone</title>
            <description>Androsterone level will be measured in the urine sample.</description>
          </group>
          <group group_id="O4">
            <title>Etiocholanolone</title>
            <description>Etiocholanolone level will be measured in the urine sample.</description>
          </group>
          <group group_id="O5">
            <title>5Œ±Adiol</title>
            <description>5Œ±Adiol level will be measured in the urine sample.</description>
          </group>
          <group group_id="O6">
            <title>5Œ≤Adiol</title>
            <description>5Œ≤Adiol level will be measured in the urine sample.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suspicious Steroid Profile in Urine Samples at Baseline</title>
          <description>Participants were asked to provide 3 urine samples at Day 1, Day 3, Day 5 to measure their baseline urinary steroid marker levels. To accommodate participant schedules, all baseline samples were collected within a two week timeframe. This outcome is measuring if any participants baseline urine samples resulted in a suspicious steroid profile. For this study, &quot;suspicious&quot; is defined as any urine sample resulting in testosterone steroid detection above 200ng/mL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone Level in Blood as Measured for Safety</title>
        <description>Testosterone level in blood to ensure safety levels of testosterone prior to (Day 0) and after the first two weeks of drug administration (Day 19). Steroid levels below the normal range were considered safe to continue study participation.</description>
        <time_frame>Day 0 and Day 19</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serum Testosterone - Day 0</title>
            <description>Serum Testosterone at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Serum Testosterone - Day 19</title>
            <description>Serum Testosterone at Day 19</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Level in Blood as Measured for Safety</title>
          <description>Testosterone level in blood to ensure safety levels of testosterone prior to (Day 0) and after the first two weeks of drug administration (Day 19). Steroid levels below the normal range were considered safe to continue study participation.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.4" lower_limit="300" upper_limit="1080"/>
                    <measurement group_id="O2" value="373.4" lower_limit="300" upper_limit="1080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Testosterone</title>
          <description>All participants will be receiving intranasal testosterone and will follow the same study procedures.
Testosterone: Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Geoffry Miller</name_or_title>
      <organization>Sports Medicine Research &amp; Testing Laboratory</organization>
      <phone>801-994-9519</phone>
      <email>gmiller@smrtl.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

